Introduction
Interest in hepcidin expression by immune-system cells has been closely linked to the documented functions of hepcidin in innate immunity (reviewed in Porto & de Sousa, 1 and in Ganz 2 ) and as a regulator of iron metabolism (reviewed in Nemeth & Ganz 3 ). Hepcidin expression has been reported in polymorphonuclear neutrophils, 4 macrophages 5, 6 and peripheral blood mononuclear cells (PBMCs) 7 in different models of infection. In an extensive study of the hepcidin gene and protein in the gilthead seabream, 'surprisingly' hepcidin expression was found also in lymphocytes. 8 In that study, hepcidin expression occurred in cells responding to the mitogens phytohaemagglutinin and concanavalin A. Recently, a case report of a C282Y HFE homozygous haemochromatosis (HH) patient, with the non-infectious, autoinflammatory, lymphoproliferative Schnitzler's disease, documented lower levels of transferrin saturation and serum iron levels at times of exacerbation of the lymphoproliferative disease, raising the question of whether lymphocytes could participate in the regulation of serum iron levels. 9 Spontaneous iron overload with high transferrin saturation has been reported in mice with defective numbers of lymphocytes. [10] [11] [12] Low CD8 + T-lymphocyte numbers have been related to severity of iron overload in HFE-HH. 13, 14 In this article we documented the expression of hepcidin in human resting peripheral blood lymphocytes (PBLs), which was up-regulated after exposure to fully saturated transferrin, ferric citrate and specific activation via CD3. Although hepcidin expression was seen in all mononuclear cell sets, this study focused mainly on T lymphocytes. Interestingly, but perhaps not surprisingly, tumour necrosis factor-a (TNF-a) appeared as a novel player with a role in hepcidin expression by lymphocytes.
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Summary
Hepcidin regulates intracellular iron levels by interacting with and promoting the degradation of ferroportin, a membrane protein and the only known cellular iron exporter. Studies of hepcidin expression and regulation have focused on its effects in innate immunity and as a regulator of systemic iron metabolism. In the present study we characterized the expression of hepcidin messenger RNA (mRNA) in human peripheral blood mononuclear cells (PBMCs) with a focus on peripheral blood lymphocytes (PBLs). We found that (1) all human PBMCs analyzed express basal hepcidin mRNA levels; (2) hepcidin mRNA expression increases after T-lymphocyte activation; (3) expression by PBLs increases in response to challenge by holotransferrin (Fe-TF) and by ferric citrate in vitro; (4) the Fe-TF-mediated up-regulation of hepcidin decreases ferroportin expression at the cytoplasmic membrane of PBLs; and (5) silencing of tumour necrosis factor-a (TNF-a) abrogates the effect of Fe-TF. In summary, we show that hepcidin expression determines intracellular iron levels by regulating the expression of ferroportin, as described in other cells, and that inappropriately low expression of hepcidin impairs normal lymphocyte proliferation. The results establish hepcidin as a new player in lymphocyte biology.
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I M M U N O L O G Y O R I G I N A L A R T I C L E
Materials and methods
Human PBMC donors
Blood donors (n = 18) were randomly recruited from the Santo Antó nio Hospital (Porto, Portugal) Blood Bank. Seven men (mean age 42 ± 7 years, range 28-54) and 11 women (mean age 40 ± 5 years, range 24-49 years) were included. Informed consent to participate in the study was obtained from all recruited subjects, according to the 1975 Declaration of Helsinki, after approval from the Hospital's Ethical Committee.
Isolation of PBMCs
PBMCs from healthy human blood donors were isolated by gradient centrifugation over Lymphoprep (Nycomed, Zurich, Switzerland) and washed with Hanks' balanced salt solution (HBSS) or phosphate-buffered saline (PBS). When appropriate, contaminating erythrocytes were lysed in 10 mM Tris, pH 7Á4, 150 mM NH 4 Cl, at 37°for 10 min. Cells were then pelleted, resuspended in RPMI medium (GibcoBRL, Carlsbad, CA) supplemented with 10% fetal calf serum (FCS; GibcoBRL) and plated.
HFE genotyping
HFE genotyping of all human subjects was performed by denaturing high-performance liquid chromatography (DHPLC), according to an established protocol. 15 
Purification of cell populations from PBMCs
For lymphocyte enrichment, each PBMC suspension was seeded at a concentration of approximately 20 · 10 6 cells/ ml in T75 culture flasks, then incubated for 2 hr at 37°in an atmosphere of 5% CO 2 . Cells in suspension (PBLs) were collected, washed in HBSS and the lymphocytes were purified using a fluorescence-activated cell sorter (FACSCalibur; Becton Dickinson, Franklin Lakes, NJ) on the basis of their light-scattering properties. The percentage of lymphocytes in the suspension was found to be always > 95%. CD4 + , CD8 + , CD14 + and CD19 + cells were purified from PBMCs using magnetic antibody cell sorting (MACS), after incubation of the PBMCs with CD4, CD8, CD14 or CD19 Microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany), following the manufacturer's instructions.
Isolation and incubation of fresh mouse hepatocytes
Hepatocyte isolation was performed by collagenase perfusion, as previously described. 16 Immediately after isolation, fresh hepatocytes were incubated with 5 mg/ml of holotransferrin (Fe-TF; Sigma, St Louis, MO; saturation > 97%), 5 mg/ml of apotransferrin (TF; Sigma), 50-100 lM ferric citrate or 100 lM sodium citrate, for 3 hr. Control cells were incubated with carrier (H 2 O). Cell viability was determined using the lactate dehydrogenase (LDH) leakage method.
In vitro treatments
For transferrin treatments, PBLs were plated in FCS-free RPMI and the medium was supplemented with 0Á5-5 mg/ ml of Fe-TF or 5 mg/ml of TF, for different periods of time. Negative controls were incubated with carrier (H 2 O). As preliminary results showed that the best response to Fe-TF was obtained after 6 hr of incubation (data not shown), subsequent treatments were all performed using an incubation of 6 hr. To control for the specificity of the Fe-TF effect, cells were co-incubated with 5 mg/ml of Fe-TF + 12 lg/ml of anti-transferrin receptor 1 (TFR1)-blocking antibody 42/6 (Calbiochem, Merck Chemicals, Nottingham, UK). All experiments were performed at least three times.
For non-transferrin-bound iron (NTBI) treatments, PBLs were plated in FCS-free RPMI and the medium was supplemented with 25-100 lM ferric citrate (Fisher Scientific, Waltham, MA) or 100 lM sodium citrate (Sigma). To control for the specificity of the iron effect, 50 lM of desferrioxamine (DFO; Novartis Pharma, Basel, Switzerland) was added to some of the wells. The possible contribution of transferrin-bound iron to the results obtained was tested by co-incubating PBLs with 100 lM ferric citrate + 12 lg/ml of anti-TFR1-blocking antibody 42/6. All experiments were performed three times.
For bone morphogenetic protein 9 (BMP9) supplementation, PBLs, and CD4 + , CD8 + , CD14 + , CD19 + , Jurkat and HepG2 cells were incubated with RPMI [or Dulbecco's modified Eagle's minimal essential medium (DMEM), for HepG2 and CD14
+ cells] supplemented with 10% FCS or with FCS-free medium. Cells were then treated with 200 ll of recombinant BMP9 (a gift of Dr Hal Drakesmith, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK), for 6 and 24 hr. Total RNA was extracted and hepcidin (HAMP) messenger RNA (mRNA) expression was assessed using quantitative real-time polymerase chain reaction (qRT-PCR), as described below.
For hepcidin supplementation, PBLs were incubated with RPMI supplemented with 10% FCS and treated with 1 lg/ml of purified native human hepcidin (described in Theurl et al. 6 ), for 6 hr. For TNF-a treatments, PBLs were incubated in RPMI supplemented with 10% FCS and with 0Á5, 5 and 50 ng/ ml of recombinant human TNF-a (R&D Systems, Minneapolis, MN), for 6 hr. To control for the specificity of the TNF-a effect, PBLs were either co-incubated with TNF-a and 40 ng/ml of anti-human anti-TNF-a monoclonal antibody (mAb) (clone 1825; R&D Systems) or were incubated with anti-TNF-a antibody alone.
Lymphocyte activation
PBLs were seeded in 96-well plates, activated with platebound mouse anti-human anti-CD3 (OKT-3; BioLegend, San Diego, CA) and 2 lg/ml of soluble mouse anti-human anti-CD28 (clone 28.2; BD Pharmingen, Erembodegem, Belgium), in RPMI supplemented with 10% FCS, and followed for a total of 72 hr. Mouse IgG was used as a negative control. mRNA expression of the activation markers interleukin (IL)-2, interferon-c (IFN-c) and TNF-a was assessed every 24 hr by qRT-PCR. Lymphocyte proliferation was assessed using the 5-bromo-2-deoxyuridine (BrdU) cell-proliferation assay (Calbiochem), following the manufacturer's instructions.
Small interfering RNAs (siRNAs)-mediated silencing
Small interfering RNAs targeting HAMP and TNFA mRNAs, as well as irrelevant scrambled siRNAs, were purchased from Eurogentec (Seraing, Belgium) and transiently transfected into PBLs using the Amaxa Nucleofector system (Lonza, Cologne, Germany). Briefly, 4 · 10 6 cells were re-suspended in 100 ll of Human T Cell Nucleofector Solution (Amaxa), mixed with 100 nM-1 lM of target-specific and siRNA-negative control duplex, and electroporated using the U-014 settings (specific for non-activated T lymphocytes). The effect of siRNA nucleofection on specific mRNA levels was quantified using the qRT-PCR.
Transfection of ferroportin-green fluorescent protein (GFP) in lymphocytes
Construction of the emerald green fluorescent protein (EmGFP) N-terminally-tagged ferroportin (FPN-GFPNterm) expression clone has been previously described. 6 Total lymphocytes were transfected with 2Á5 lg of FPN-GFP-Nterm or with 2Á5 lg of pmaxGFP (Amaxa Biosystems), using the Amaxa Nucleofector system and following the same procedures described for siRNA transfection.
Assessment of iron traffic
The ability of PBLs to accumulate iron was assessed using ( 55 Fe)-TF. Saturation of TF (Sigma) with 55 Fe (Amersham, Barrington, IL) was performed as previously described. 17 PBLs were incubated in FCS-free RPMI with 0Á5-lmol/l of ( 55 Fe)-TF, for up to 24 hr. After each incubation period, the PBLs were washed three times with ice-cold washing buffer [10 mM Hepes, pH 7Á3, 1 mM nitrilotriacetic acid (NTA), 150 mM NaCl], lysed with 0Á1% Triton X-100 and intracellular 55 Fe was measured in a 1450 MicroBeta Trilux b-counter (Perkin Elmer, Waltham, MA), with a 0-350 nm window, for 1 min. An aliquot of each cell suspension was used for quantification of the cell number in each well. All of the samples were assayed in triplicate.
Holotransferrin intake was assessed using 100 nM 125 I-labelled TF-Fe (Amersham), for up to 24 hr. An aliquot of each lysate was used to quantify total protein content, using the RC/DC Protein Assay (Bio-Rad, Hercules, CA). All samples were assayed in triplicate. The results are expressed as ng of 125 I-labelled TF/mg of total protein. Three independent experiments were performed.
To assess iron export, PBLs were incubated with 0Á5-lmol/l of ( 55 Fe)-TF, for up to 24 hr, as described for the iron-accumulation assays. Cells were then washed three times with ice-cold washing buffer, to remove cell membrane-bound iron, and transferred to FCS-free RPMI for up to 24 hr. At specific time-points, cells were solubilized with 0Á1% Triton X-100 and intracellular 55 Fe was measured, as described previously. An aliquot of each cell suspension was used to quantify the cell number in each well. Three independent experiments were performed.
Real-time PCR
Total RNA was extracted using the RNeasy Midi kit (Qiagen) or the RNeasy Plus Mini kit (Qiagen, Hamburg, Germany), with on-column DNAse I digestion (Qiagen). Complementary DNA (cDNA) was synthesized using the Superscript First-Strand Kit (Invitrogen, Paisley, UK) and qRT-PCR was performed in an iCycler iQ5 PCR detection system (Bio-Rad), using specific primers (Table 1) . Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression was used as an internal control for most experiments. Although some previous studies reported changes in GAPDH expression caused by iron exposure in cell and in vivo models, 18 in our experimental conditions, and for the cell types used in the present study, we did not find any evidence of the modulation of GAPDH mRNA levels by any of the treatments applied. For experiments involving cell activation, however, GAPDH was found to be an inadequate control (data not shown), confirming previous reports, 19 and 18S ribosomal RNA (rRNA) expression was used instead. Relative expression levels were calculated as 2 (Ct human GAPDH or 18S endogenous control gene -Ct gene of interest)*1000
. For every gene a dilution series of four serial dilutions was used during optimization of the procedure. All experiments involving qRT-PCR were performed at least in triplicate, with two to three replicates each.
Immunofluorescence
Flow cytometry PBLs were harvested post-treatment, fixed for 15 min in 3Á5% paraformaldehyde (PFA), at room temperature, and either analyzed immediately or incubated for 30 min with 100% mouse anti-human HFE-8C-10 supernatant (a gift of Dr Rachel Ehrlich, Tel Aviv University, Israel), followed by a 20 min incubation with 5 lg/ml of donkey anti-mouse labelled with fluorescein isothiocyanate (FITC) (Jackson ImmunoResearch, Suffolk, UK). Cells were then washed, and the GFP/FITC fluorescence was analyzed in a Becton-Dickinson FACSCalibur, at FL1. Values are expressed as a function of cell autofluorescence.
Confocal microscopy PBLs were harvested post-treatment, fixed for 15 min in 3Á5% PFA and blocked with PBS containing 10% FBS. Fixed cells were incubated for 30 min with, alternatively, a 1 : 11 dilution of mouse anti-human phycoerythrin (PE)-conjugated anti-CD3 (Miltenyi Biotec), 1 lg/ml of rabbit anti-human anti-large multifunctional protease 2 (LMP2) (Abcam, Cambridge, MA), a 1 : 5 dilution of mouse anti-human lysosome-associated membrane protein 2 (LAMP2) (clone H4B4; developed by August & Hildreth and maintained by the University of Iowa, USA), or 100% mouse anti-human HFE-8C-10 supernatant. Donkey anti-mouse-FITC (5 lg/ml; Jackson), donkey anti-rabbit-cyanine 3 (Cy3) (5 lg/ml; Jackson) or goat anti-mouse Alexa Fluor 568 (20 lg/ml; Molecular Probes, Paisley, UK) were used as secondary conjugated antibodies. Cells were then cytospinned on slides and mounted in a 1 : 5 dilution of 4 0 ,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich)/Vectashield (Vector, Burlingame, CA). Confocal analysis was performed on a Leica (Leica Microsystems CMS, Bannockburn, IL) TCS SP2 AOBS microscope: a Blue diode laser (405 nm) was used for DAPI; an Ar laser (488 nm) was used for GFP/FITC; and an HeNe laser (543 nm) was used for Cy3/Alexa 568.
Labelling and immunoprecipitation of hepcidin
Human PBLs and the human hepatoma cell line HepG2 were plated in six-well plates and depleted of intracellular cysteine and methionine by incubation for 4 hr in cysteine-free and methionine-free RPMI-1640 (Sigma) medium supplemented with 5% dialysed FCS (Sigma). De novo synthesized proteins were then labelled by the addition of 40 lCi of ( 35 S)Cys-Met (Easy Tag Express Protein Labeling Mix; Perkin Elmer) and of 25 lCi of ( 14 C)-amino acid mixture (Perkin Elmer), followed by Fe-TF (for PBLs) and BMP9 (for HepG2) supplements. Cells were incubated overnight at 37°. Culture medium was collected and one-third was transferred to 1Á5-ml tubes and centrifuged to remove cell debris. Supernatant was transferred to fresh 1Á5-ml tubes containing protease inhibitor cocktail (Sigma) and precleared with 20 ll of Protein A-agarose (Santa Cruz Biotechnology, Santa Cruz, CA) for 30 min at 4°. Beads were pelleted by centrifugation and the supernatants were transferred to fresh 1Á5-ml tubes containing protease inhibitor cocktail, followed by incubation with 30 ll of rabbit antiserum directed to the mature synthetic refolded hepcidin peptide (amino acids 60-84; a gift of Dr Tomas Ganz, David Geffen School of Medicine at UCLA, Los Angeles, USA) for 2 hr, at 4°. A rabbit anti-human CCAAT/enhancer-binding protein, alpha (C/EBP-a) antibody was used as a non-specific control. Protein A-agarose was added as a 50% slurry in PBS and mixed overnight at 4°. The agarose was washed four times with PBS and the immunoprecipitate was eluted by incubation in 30 ll of 3· sample loading buffer [170 mM Tris-HCl, pH 8Á8, 21% (wt/vol) glycerol, 6% (wt/vol) sodium dodecyl sulphate (SDS), 120 mM dithiothreitol] at 4°, overnight. The elute was boiled for 15 min and radiolabelled hepcidin was separated on a 19% SDS-Tricine polyacrylamide gel with a 4% polyacrylamide stacking layer, stained with Coomassie Blue, destained, soaked in Amplify (Amersham), dried and exposed to Kodak BioMax MR X-ray film (Eastman Kodak, Rochester, NY) for 72 hr, at )80°.
Western blot analysis
Western blot analysis of FPN-GFP expression in the cytoplasmic membrane of PBLs was performed as described previously. 6 A rabbit anti-human FPN antibody (1 : 100 dilution) 6 was used to detect FPN-GFP, and a rabbit anti-human b-actin antibody (2 lg/ml; Abcam) was used as a loading control. Normalization of band intensities was performed using IMAGEJ. 20 
Statistical analysis
The results are expressed as average values +1 standard deviation (SD). Statistical differences between means were calculated using the Student's unpaired t-test. For experiments involving multiple treatment groups, one-way analysis of variance (ANOVA) was used to test for significant differences among sample means. When significant differences were detected, the data were re-analyzed using the Bonferroni post hoc test. Statistical significance was set at P < 0Á05. All statistical analyses were performed using STATGRAPHICS Centurion XV (Statpoint Technologies, Herndon, VA).
Results
Hepcidin mRNA is expressed in all mononuclear cell sets Hepcidin mRNA expression was first analyzed in total human PBMCs (n = 18) (Fig. 1) (Fig. 2a,b) . No effect was observed in the expression of hepcidin when the PBLs were treated with TF or sodium citrate. Hepcidin induction was abrogated when PBLs were co-incubated with Fe-TF/a-TFR1-blocking antibody 42/6 or with ferric citrate/50 lM DFO, respectively. As a negative control for the effect of NTBI, the effect of Fe-TF/TF and of ferric citrate/sodium citrate in hepcidin expression was tested in fresh mouse hepatocytes, showing that while Fe-TF induces a twofold increase in hepcidin expression in hepatocytes, the highest doses (50 and 100 lM) of ferric citrate have no effect on hepcidin expression, relative to both mock-treated and sodium citrate-treated cells (Fig. S1) , confirming an observation first made by Nemeth et al.
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Hepcidin mRNA is potently induced by lipopolysaccharide (LPS), as well as by IL-6 and other cytokines 5 in other cell types. The possibility that the iron-induced hepcidin up-regulation could be caused by low-level contamination of the reagents with endotoxin was excluded by the lack of a significant response after treatment of PBLs with human IL-6 (data not shown) and LPS for 6 hr (Fig. S2) .
In order to check if the increase in hepcidin expression by PBLs in response to Fe-TF could be detected at the protein level, PBLs were incubated with Fe-TF or carrier, and the levels of hepcidin in the culture medium were assessed by immunoprecipitation. As a positive control, the culture medium of HepG2 cells supplemented with BPM9 for 6 hr was used. Our approach did not allow the detection of hepcidin from PBLs in any of the conditions tested, probably because of the low levels of expression of hepcidin by these cells, in comparison with stimulated HepG2 A faint band of approximately 3000 molecular weight was detected only in BMP9-stimulated HepG2 (Fig. S3) . In these conditions an increase in the hepcidin mRNA levels of > 5 · 10 3 was seen relative to control cells (Fig. S4) . These results suggest that the available tools lack sensitivity to detect hepcidin at the levels synthesized by PBLs or unstimulated hepatoma cells at the cell concentration used.
Fe-TF-mediated hepcidin up-regulation modulates FPN expression
Hepcidin regulates iron levels by interacting with the only known cellular iron exporter, the cytoplasmic membraneassociated FPN, and promoting its internalization and degradation. 21 Flow cytometry analysis showed that incubation of PBLs with Fe-TF or with 1 lg/ml of hepcidin induced a decrease in the levels of N 0 -FPN-GFP at the cytoplasmic membrane, in comparison with carriertreated and TF-treated PBLs (Fig. 3a) . In contrast, no effect of Fe-TF or hepcidin was observed in the cytoplasmic membrane levels of overexpressed HFE, another cell-surface protein that is not targeted by hepcidin. To confirm that the effect of Fe-TF on N 0 -FPN-GFP was caused by an increase in hepcidin expression by PBLs, cells overexpressing N 0 -FPN-GFP were further nucleofected with hepcidin-specific siRNAs (siHAMP) or with irrelevant scrambled siRNAs (siNeg). Silencing of HAMP mRNA to 70-80% of its original levels abrogated the reduction in cell-surface FPN in response to Fe-TF (Fig. 3a, bottom panel) , confirming that an increase in endogenous hepcidin expression mediates the Fe-TFinduced reduction in FPN cytoplasmic membrane levels in PBLs.
To further characterize the effect of Fe-TF/hepcidin on FPN expression in PBLs, FPN-GFP localization was analyzed by confocal microscopy. FPN-GFP was found to be located primarily at the cytoplasmic membrane of TF-treated PBLs (Fig. 3b, panel a) and was co-localized with the cell-surface T-lymphocyte marker CD3 (panels d-f). Incubation of PBLs with Fe-TF disturbed the FPN cell-surface localization (panel b), causing the internalization of FPN-GFP and its co-localization with the 20S proteasome marker LMP2 (panels g-i). Incubation with 1 lg/ml of hepcidin caused an even more pronounced Hepcidin expression increases in human PBLs in response to ferric citrate. PBLs were incubated with ferric citrate (Fe-Cit), sodium citrate (Na-Cit), ferric citrate + anti-TFR1 blocking antibody 42/6 (Fe-Cit + 42/6), 50 lm desferrioxamine (DFO) or ferric citrate + 50 lm desferrioxamine (Fe-Cit + DFO) and the hepcidin mRNA levels were assessed using the qRT-PCR. The results are expressed as average fold induction (+1 SD) relative to hepcidin levels in mock-treated cells. *Significant difference (P < 0Á01) between treatments and the Mock control (one-way anova).
effect on FPN internalization and co-localization with LMP2 (panels c and j-l). No clear co-localization was observed between FPN-GFP and the lysosomal marker, LAMP2, after incubation with Fe-TF (data not shown).
No effect of Fe-TF or hepcidin was observed in the localization of overexpressed HFE (panels m-o), thus confirming the results obtained with the flow cytometry analysis.
TNF-a is necessary for hepcidin modulation by Fe-TF
Modulation of hepcidin expression by iron has been described in hepatocytes, through a mechanism whereby Fe-TF modulates the binding of HFE to the TFR2 or TFR1 proteins, at the cytoplasmic membrane of hepatocytes, and the consequent signalling of a (BMP)/mothers against decapentaplegic (SMAD) cascade. 22 The absence of detectable expression of HFE and TFR2 in PBLs 23, 24 heralded that this pathway might not be involved in hepcidin modulation by iron in lymphocytes. Similarly, the regulatory role of the BMP pathway in hepcidin transcription described in hepatocytes 25 does not seem to be present in lymphocytes. Indeed, no response was observed in PBMCs, in CD4 + , CD8 + , CD14 + and CD19 + cell populations, or in the leukaemic T-cell line, Jurkat, after incubation with exogenous BMP9, in marked contrast with a hepcidin up-regulation of > 5 · 10 3 in the hepatoma cell line HepG2 (Fig. S4) .
Hypothesizing that in vivo hepcidin expression in lymphocytes must occur in a tissue context involving cytokines, and aware of recent evidence demonstrating (FPN-N) , pcDNA3-HFE (HFE) or with pcDNA3 plasmid alone (Mock). For some experiments, FPN-N-transfected cells were re-transfected with small interfering RNAs (siRNAs) targeting human hepcidin (siHAMP) or with irrelevant siRNAs (siNeg). Cells were then supplemented with 5 mg/ml of Fe-TF, 5 mg/ml of apotransferrin (TF) or 1 lg/ml of hepcidin, for 6 hr. H 2 O was used as a carrier control. FPN-GFP and HFE were quantified at the cytoplasmic membrane of PBLs using flow cytometry. Two independent experiments were performed. (b) Fe-TF and hepcidin induce internalization of ferroportin in human PBLs. PBLs were transfected with the EmGFP N-terminally-fused ferroportin, or with HFE, and supplemented with Fe-TF, TF or hepcidin, as described for (a). Localization of FPN-GFP, as well as co-localization with the CD3 T-lymphocyte marker for the cytoplasmic membrane and the large multifunctional protease 2 (LMP2) marker for the 20S proteasome unit, was detected using laser confocal microscopy. Bar = 10 lm.
that the particular impact of TNF-a in cellular immunity was not related to infection, 26 we tested whether cytokine expression could be modulated in human PBLs in response to Fe-TF. Incubation of PBLs with increasing concentrations of Fe-TF induced a corresponding dosedependent increase in TNFA (coding for TNF-a) mRNA expression, in comparison to mock or TF-treated cells (Fig. 4a) . The specificity of the effect is supported by the abrogation of an increase in TNFA when Fe-TF-treated PBLs were co-incubated with an anti-TFR1 blocking antibody. No effect of Fe-TF was observed in the expression of IL2, IL4 or IFG (coding for IFN-c) mRNAs (Fig. 4a ).
To further demonstrate the possible involvement of TNF-a in the modulation of hepcidin expression by Fe-TF, lymphocytes were transfected with siRNAs targeting TNFA mRNA, followed by treatment with Fe-TF or TF. Knockdown of TNFA mRNA to 70-75% of its basal levels in lymphocytes (data not shown) abrogated the up-regulation of hepcidin by Fe-TF (Fig. 4b) . Transfection with an irrelevant scrambled siRNA did not affect hepcidin induction. Although not statistically significant, a trend for a reduced basal hepcidin expression was observed when cells were treated with siTNFA alone. As a control, knockdown of CD8 mRNA to approximately 70% of its Figure 4 . Tumour necrosis factor-a (TNF-a) mediates hepcidin induction by holotransferrin (Fe-TF) in lymphocytes. (a) TNFA expression is modulated by Fe-TF. Human peripheral blood lymphocytes (PBLs) (n = 9) were plated and treated with 0Á5-5 mg/ml of Fe-TF or 2Á5-5 mg/ml of apotransferrin (TF), for 6 hr. The anti-transferrin receptor 1 (anti-TFR1) blocking antibody 42/6 was used as a specificity control. The messenger RNA (mRNA) levels of IL2, IL4, IFG and TNFA were quantified using the quantitative reverse transcription-polymerase chain reaction (qRT-PCR). *Significant difference (P < 0Á01) between treated samples and the Mock control [one-way analysis of variance (anova)]. (b) TNF-a silencing impairs the peripheral blood lymphocyte (PBL) response to Fe-TF. PBLs were either left untreated or were transfected with small interfering RNAs (siRNAs) for TNFA (siTNFA) or with irrelevant siRNAs (siNeg). After treatment with 5 mg/ml of Fe-TF, 5 mg/ml of TF or H 2 O, the HAMP mRNA levels were quantified using the qRT-PCR. * Significant difference (P < 0Á05) relative to the Mock control (Student's t-test). (c) Exogenous TNF-a induces hepcidin expression in PBLs. Human PBLs (n = 3) were treated with 0Á5-50 ng/ml of recombinant human TNF-a (rhTNF-a), and/or with an anti-TNF-a neutralizing monoclonal antibody (mAb). The hepcidin mRNA levels were quantified using the qRT-PCR. All qRT-PCR results are expressed as average fold induction [+1 standard deviation (SD)] relative to Mock-treated cells. *Significant difference (P < 0Á01) between treated samples and the Mock control [one-way analysis of variance (anova)]. **Significant difference (P < 0Á05) in HAMP expression between TNF-a + anti-TNF-a-treated cells and cells treated with 50 ng/ml of TNF-a (Student's t-test).
basal levels was used, failing to affect the response of hepcidin to Fe-TF (data not shown).
The involvement of TNF-a was tested further by incubating human PBLs with increasing concentrations of recombinant human TNF-a (rhTNF-a). All concentrations of rhTNF-a induced a significant increase in hepcidin expression (Fig. 4c) , a result that was abrogated when TNF-a-treated PBLs were co-incubated with an anti-TNF-a antibody.
Collectively, these results indicate that TNF-a is involved both in the basal and Fe-TF-induced mRNA expression of hepcidin in human PBLs. Fe levels ± 1 SD of three experiments. * and ** indicate significant differences (P < 0Á05 and P < 0Á005, respectively) in the 
Hepcidin expression controls iron export from activated lymphocytes
Iron is an essential element for DNA synthesis and cell division. 27 This knowledge, together with the present results, prompted the question of whether hepcidin could affect lymphocyte iron levels after activation. To test that hypothesis, lymphocytes were activated with anti-CD3/ anti-CD28 antibodies and the effect on hepcidin expression was assessed. Activation induced a significant (P < 0Á05) increase in hepcidin expression in PBLs at 72 hr, with a trend for slightly higher hepcidin expression at 24 and 48 hr, although not significantly different from baseline levels (Fig. 5a ). The effectiveness of lymphocyte activation was confirmed by the increased expression of the activation markers IFN-c, TNF-a and IL-2 (data not shown).
The modulation of hepcidin expression after lymphocyte activation could reflect a novel mechanism of control of intracellular iron levels in a situation of high iron demand. To test this hypothesis, PBLs were transfected with hepcidin-specific siRNAs, activated and incubated with ( 55 Fe)-TF for up to 24 hr. Intracellular 55 Fe levels reached a maximum between 3 and 8 hr in all experimental conditions. However, from 8 hr of incubation onwards, the levels of 55 Fe were significantly lower in hepcidin-depleted cells, in comparison with the siNeg controls (Fig. 5b) . Supplementation of culture medium with 1 lg/ml of hepcidin corrected the iron levels of hepcidin-depleted cells, pointing to the specificity of the effect of hepcidin.
To determine whether the observed differences in intracellular iron levels were caused by a reduction in iron intake or by an increase in iron export, PBLs were nucleofected with HAMP-specific or control siRNAs and activated, as described, followed by incubation with 125 I-labelled TF-Fe. No differences were observed in the levels of 125 I between hepcidin-silenced and control cells (Fig. 5c) , suggesting that hepcidin does not affect TF-mediated iron import. However, when PBLs submitted to the same protocol were loaded with ( 55 Fe)-TF and then incubated in iron-free medium for up to 24 hr, a significant decrease in intracellular 55 Fe levels was observed in the hepcidin-depleted cells (Fig. 5d) , suggesting that increased iron export is the cause for the lower intracellular iron levels induced by hepcidin depletion in activated lymphocytes. Supporting this finding, higher protein levels of the iron exporter FPN were recovered in activated hepcidin-depleted lymphocytes, in comparison with cells transfected with control siRNAs or supplemented with exogenous human hepcidin (Fig. 5e) .
Finally, it seemed relevant to determine whether the hepcidin-induced changes in intracellular iron levels could affect lymphocyte proliferation itself. Hepcidin was silenced with HAMP-specific siRNAs followed by activation of lymphocytes. Silencing of hepcidin mRNA to Figure 6 . Hepcidin expression is necessary for normal lymphocyte proliferation. (a) Hepcidin levels modulate lymphocyte proliferation. Peripheral blood lymphocytes (PBLs) were transfected with siHAMP/siNeg siRNAs and activated as described in the Materials and methods. As a positive control for the effect of hepcidin, treatment with 1 lg/ml of purified native human hepcidin was performed. Cell proliferation was measured by the incorporation of 5-bromo-2-deoxyuridine (BrdU). Values represent the average +1 standard deviation (SD) of three experiments. * and ** indicate statistical differences (P < 0Á05 and P < 0Á005, respectively) in BrdU incorporation between control cells and, respectively, hepcidinsupplemented and hepcidin-silenced cells (Student's t-test). (b) Phase-contrast microscopy of a representative example (n = 3) showing the formation of lymphocyte aggregates at 48 hr post-activation in lymphocytes transfected with siHAMP or siNeg siRNAs. Bars = 500 lm. siHAMP, hepcidin-specific siRNAs; siNeg, irrelevant siRNAs; siRNAs, small interfering RNAs. approximately 10% of its original levels diminished lymphocyte proliferation significantly (P < 0Á005) (Fig. 6a) , a result that was particularly striking when the lymphocytes were analyzed using phase-contrast microscopy (Fig. 6b) . Rescue of lymphocyte proliferation was obtained after coincubation with native human hepcidin (Fig. 6a) .
Taken together, these results show (1) that there is a variation in the expression of hepcidin in the course of the response of T-lymphocyte activation; (2) that the variation affects iron export in a way that influences cell proliferation and cell-surface FPN levels; and (3) that the sum of (1) and (2) reveals a putative novel function for hepcidin.
Discussion
The observation that lymphocytes express hepcidin was pioneered by Cuesta et al. 8 in the guilthead seabream, providing additional credence to the importance of this small protein/antimicrobial peptide and illustrating, at the same time, the power of economy in evolution. Thus, what started by being a small antimicrobial peptide of use in innate immunity responses moves to regulate iron fluxes in key cells for mammalian systemic iron metabolism. The present results confirm also the up-regulation of hepcidin expression after lymphocyte activation that was first reported in the gilthead seabream 8 and narrow it to activation through CD3. The serendipitous use of CD3 as a control for the membrane localization of GFP-FPN brought to light the exact co-localization of the two molecules at the cell surface, an intriguing observation that should deserve greater attention in the future. In addition, it was found that decreased hepcidin levels during activation may influence lymphocyte proliferation by diminishing intracellular iron levels related to an increase in the iron exporter FPN. This can be construed as evidence for a possible new role for hepcidin beyond innate immunity, or indeed immunity, into regulation of cell proliferation. A need for adequate intracellular iron levels for the translation of cytokine mRNAs was shown earlier by Wang et al. 28 in a study of macrophages from Hfe
mice.
One of the hallmarks of all immune-system cells in vivo is the ability to circulate in the blood and, in the case of lymphocytes, to recirculate continuously between the blood and lymph. In principle, confirmation of the exact relevance of the present results to the in vivo situation should await construction of a mouse with hepcidin gene expression specifically deleted in the bone marrow-derived lympho-myeloid cell lineage. Nevertheless, that in itself may prove to be insufficient in view of the fact that neutrophils, for example, produce lactoferrin, another potent iron-binding protein capable of holding on to iron at the low pH in inflammatory sites. 29 Slight increases in transferrin saturation were found in LF )/) mice. 30 Human T lymphocytes have been shown to synthesize H ferritin. 31 Ferritin H is also regulated by TNF-a. 32 Thus, studies of transferrin saturation and NTBI in such an animal model selectively defective in lymphomyeloid cell hepcidin may not give unequivocal results. Evidence must be sought therefore in other so-called 'experiments of Nature' characterized by selective or total lymphopenias, where serum iron levels and transferrin saturation have been measured (an infrequent event). The fact that current tools proved not to be sufficiently sensitive to detect the protein in unstimulated hepatoma cells or PBLs makes the need for telling experimental models even greater. For instance, it has been documented for some time that spontaneous iron overload develops in b 2 m )/) mice, 10, 33 and that more severe forms of iron overload are found in Hfe )/) and b 2 m )/) mice crossed either between themselves 34 or with other complete lymphocyte-depleted mice (Rag )/) ) 11 and in mice specifically lacking CD8 + cells. 12 Low CD8 + lymphocyte numbers have also been observed consistently in HH patients with severe iron overload. 13, 35 In humans, sequential increases in TF saturation and NTBI levels are well documented in patients undergoing aggressive chemotherapy and conditioning for allogeneic or autologous stem cell transplantation. [36] [37] [38] Although the notable increases in TF saturation and NTBI seen within 24-48 hr of the start of aggressive chemotherapy are generally attributed to the failure of iron being utilized for erythropoiesis, the present results bring to the fore the possibility that the direct peripheral pancytopenia created by some chemotherapy protocols could provide an additional contribution to the increases in TF saturation and NTBI reported. The clear association of the highest NTBI levels with the most severe leukopenias 38 is in keeping with this interpretation. NTBI, by catalyzing hydroxyl radicals, poses threats that may or may not be directly related to infection 39 but that are equally deserving of surveillance.
The up-regulation of hepcidin expression now seen in activated lymphocytes can also relate to the reported changes in serum iron levels seen in experimental and/or clinical models of acute inflammation known to involve lymphocyte activation. 9, 40 Finally TNF-a also made its entrance as a significant player in determining lymphocyte hepcidin expression. Although we are aware that the present work does not fully allow us to speculate on the possible in vivo significance of the results, the present finding of a role for TNF-a in lymphocyte hepcidin expression is compatible with the recently documented necessary interaction of TNF-a with CD4 + cells in the development of DTH responses in young subjects. 26 In summary, the present results obtained in vitro, and the results of other observations in humans and in mice, warrant the conclusion that hepcidin could join the armory of surveillance beyond innate immunity. In addi-tion, they indicate that hepcidin has a regulatory role in intracellular iron homeostasis and cell proliferation, at least in lymphocytes. The results of two recent papers on hepcidin induction in response to ER stress 41, 42 provide further evidence for the capacity of hepcidin to respond to intracellular stimuli.
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